Can you mix tirzepatide and semaglutide — or use them at the same time?

Why the trial data rules out combining them

Tirzepatide (Mounjaro) and semaglutide (Wegovy) were each developed and licensed as standalone treatments. Every trial that generated the safety and efficacy data regulators relied on tested one medicine at a time, against placebo or a comparator, not stacked together. SURMOUNT-1, published in the New England Journal of Medicine, recorded roughly 20–21% average body-weight reduction at tirzepatide's highest dose over 72 weeks. STEP 1, the equivalent semaglutide trial, found around 15% average loss at 2.4 mg over 68 weeks. Both are substantial results. Neither was produced by combining the drugs, they are the effect of one medicine, dosed carefully, alongside dietary and activity changes.

There are no published randomised trials examining the safety of co-administration. That absence is not an oversight; it reflects the fact that both medicines affect gastric emptying, appetite signalling and GI function through related mechanisms. Running them simultaneously would be pharmacologically unpredictable and, given the GI side-effect profile of each individually, the risk of compounding adverse effects is real. The NHS medicines page for tirzepatide is explicit that it should not be taken with other GLP-1 receptor agonists, and while tirzepatide is a dual GIP/GLP-1 agonist rather than a pure GLP-1, the principle holds.

The licensed indication for each medicine specifies it as a single treatment alongside lifestyle changes, not as an addition to another weight-loss injection. If you are wondering whether you can mix semaglutide and Mounjaro, the answer the evidence supports is that using them together would fall outside those licences entirely.

What the head-to-head evidence actually shows

The reason many people wonder about combining the two is understandable: they have heard that each works, and want more. But the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, addressed the relevant question directly, not whether you can stack the medicines, but which one produces greater results when used properly. In that 72-week open-label trial involving 751 adults with obesity and no diabetes, tirzepatide produced greater average weight reduction than semaglutide 2.4 mg. NICE's appraisal of tirzepatide (TA1026) noted that indirect comparisons also favour tirzepatide, though it acknowledged the limitations of cross-trial comparison.

Wegovy's higher 7.2 mg dose, approved by the MHRA in January 2026, narrows that gap, trials at that dose reported around 20.7% average weight loss over 72 weeks, approaching tirzepatide 15 mg results. If you are trying to decide between the two options, our page on whether semaglutide or tirzepatide is right for you sets out the key considerations in one place. You can look at a direct comparison of Wegovy and Mounjaro for a fuller breakdown of how the two medicines sit alongside each other.

The upshot: the search for greater results does not run through combining medicines. It runs through choosing the right medicine at the right dose, with clinical oversight.

Switching between them: a different question, with a different answer

Switching from one to the other (under prescriber supervision, not at the same time) is a different matter. That is occasionally done clinically when a patient is intolerant of one medicine, or when the prescriber judges a switch appropriate after a proper review. It is not simultaneous use; there would typically be a gap to allow washout, and the decision rests entirely with the prescriber based on your history, current dose and response.

If you are already on one medicine and wondering whether switching might be an option, that conversation belongs in a clinical consultation, not a search engine. Our prescribers at nume's clinical team review every case individually, transfer patients provide evidence of their current treatment, and dose decisions are made on the back of that, not on a blanket protocol. There is more on the switching question at our page on taking semaglutide and tirzepatide if you want the longer version.

Comparing tirzepatide and semaglutide side by side

Since the question often comes from people deciding between the two rather than truly wanting both, here is a factual comparison. The right choice depends on your clinical picture, but this gives you the landscape before a consultation.

For a more detailed look at the cost side of the decision, this page covers how the prices compare. And if you want to understand the practicalities of mixing semaglutide and tirzepatide, that page goes deeper into why co-administration is not a clinical option. Which medicine suits you is a decision our prescribers make with you, it is rarely obvious from the outside, and the comparison table above is a starting point, not a verdict.